LEO Pharma

LEO Pharma introduces new operating model to increase competitiveness and support future growth  


- LEO Pharma introduces a new operating model and organizational structure to support its growth strategy towards 2030 - The new operating model includes optimizing the commercial and R&D organization - The changes are expected to affect around 1,000 positions in the global organization over a period of two years

Ballerup, January 19, 2022 –LEO Pharma today announced the introduction of a new operating model and change program to simplify operations, increase profitability and fund its ambitious growth strategy.    

In 2020, LEO Pharma unveiled its strategy towards 2030. The first phase of this strategic transformation process – including the introduction of a new capital and governance structure – was recently completed. Next phase, announced today, is about focusing on core business and operational efficiency, and improving competitiveness and continuous adaptation to the commercial model that best fits the company’s product portfolio and to the evolving needs and preferences of external stakeholders. Through these adjustments, LEO Pharma will be poised for delivering consecutive growth.

“We are at a defining moment in our transformation journey – and in the history of our company even.Withour strategy towards 2030, we know that we are well-positioned for a bright future within innovative medical dermatology. To release the full potential, we must now increase profitability and make bold investments in the best and most innovative treatment options for the patients we serve,” said Anders Kronborg, Chief Financial Officer and Acting CEO and President of LEO Pharma, and continued:  

“The new operating model we announce today will make a much moresimple, agile andefficient LEO Pharma and this is the best way forward for us to ensure a sustainable business model for the future.Itwillaffect employees who have served the company with loyalty and dedication for many years. We will do our utmost to support our colleagues as changes are implemented”.    

Simplified setup and focus on core business   

To further accelerate the transformation process and increase competitiveness and profitability, LEO Pharma are optimizing its commercial operating model globally and across markets to best fit its product portfolio to the evolving needs and preferences of the external environment.   

LEO Pharma’s Global R&D organization will focus the in-house drug discovery on promising small molecule technologies and further increasing productivity to realize the company’s ambition to launch a new innovative asset or enter a new indication every two to three years. Other initiatives include driving efficiencies through outsourcing; further standardization; boosting digitalization as well as centralizing systems, data and analytics. Also, LEO Pharma’s Open Innovation, Regenerative Medicine and the Science & Tech Hubs in Asia and Boston, US, will be closed as a part of the changes announced today.  

The changes are expected to affect around 1,000 positions in the global organization over the next two years. Today, the announcement has directly affected 68 people in LEO Pharma’s global organization. Final estimates for headcount impact in all areas of the business are subject to completion of applicable consultation processes.  

Poised for growth  

Since the launch of the 2030 strategy in 2020, LEO Pharma has progressed on the ambitions of transforming the company into a global leader and top five player in medical dermatology. On this journey, the recent FDA approval of tralokinumab in the US was a  major milestone and a turning point in the ability to grow to advance the standard of care for patients, their families and society by bringing innovative treatments to the market. Other key achievements include the efficiency gains and savings already delivered, and successfully expanding sales of the established product portfolio.   

By bringing tralokinumab and other innovative treatments successfully to the market and introducing the new operating model, LEO Pharma is poised for delivering consecutive double-digit growth and an EBITDA margin of 25% by 2025 preparing the company for an IPO within a four-to-five year horizon.  


Media Contact  
Henrik Heskjaer  
Director, Global External Communications  
Tel: +45 3140 6180  

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma   

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10.133 billion. For more information about LEO Pharma, visit www.leo-pharma.com.   

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

Japan Ministry of Health, Labor and Welfare Approves Manufacturing and Marketing of Adtralza® (tralokinumab) in Japan for Adults with Atopic Dermatitis23.12.2022 06:22:48 CET | Press release

BALLERUP, Denmark, 23, December 2022 – LEO Pharma A/S, a global leader in medical dermatology, announced today that the Japan Ministry of Health, Labor and Welfare (MHLW) has granted approval for the manufacturing and marketing of Adtralza® (tralokinumab) subcutaneous injection (S.C.) for adults with atopic dermatitis, which has inadequately responded to conventional therapies.

LEO Pharma announces positive phase 3 topline results from DELTA 1 trial with delgocitinib cream in adults with moderate to severe chronic hand eczema (CHE)6.12.2022 08:00:00 CET | Press release

• The first phase 3 clinical trial (DELTA 1) with delgocitinib cream in adults with moderate to severe chronic hand eczema (CHE) met primary and all key secondary endpoints • DELTA 1 trial results show that delgocitinib cream provided early symptom-relief in a hard-to-treat disease • The majority of adverse events observed were non-serious, mild or moderate in severity, and not considered treatment related


• In partnership with Global patient advocate Ashley Ann Lora, AD Days Around the World explores the impact of atopic dermatitis (AD) on the lives of individuals around the world living with this chronic and debilitating skin disease • The campaign features the emotional journey of four patient advocates from France, Italy, Germany and Spain and showcases the impact that AD has on people, regardless of culture or geography

LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis29.9.2022 07:00:00 CEST | Press release

LEO Pharma and DKSH have entered into an agreement to bring high-quality therapeutic products for dermatology and thrombosis to patients across Asia. This agreement both supports LEO Pharma’s strategy of building a simpler and more competitive organization and DKSH Business Unit Healthcare’s strategic focus of strengthening its regional footprint.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom